cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.30476831.v1
title: Effect of pressure-controlled ventilation-volume guaranteed mode on intraoperative respiratory mechanics, oxygenation and postoperative pulmonary complications: a systematic review and network meta-analysis

description: Ventilation strategies during general anesthesia are crucial for optimizing respiratory mechanics, ensuring adequate oxygenation, and minimizing postoperative pulmonary complications (PPCs) in surgical patients. This systematic review and network meta-analysis (NMA) aim to evaluate the effect of pressure controlled volume guaranteed ventilation (PCV-VG) in patients undergoing non-cardiothoracic surgery. We selected randomized controlled trials (RCTs) to explore the effect of PCV-VG mode on intraoperative respiratory mechanics, oxygenation and PPCs in surgical patients published in English by searching PubMed, Embase, Web of Science, and the Cochrane from inception to May 2025. The primary outcome was dynamic lung compliance (Cdyn). Fourteen studies with 2263 patients were included. Compared to volume-controlled ventilation (VCV), PCV-VG had higher Cdyn and lower airway peak pressure (Ppeak). For tidal volume (Vt), partial pressure of carbon dioxide in arterial blood (PaCO<sub>2</sub>), partial pressure of oxygen in arterial blood (PaO<sub>2</sub>), oxygenation index (OI), airway mean pressure (Pmean), and PPCs, there were no significant difference among pressure-controlled ventilation (PCV), VCV, and PCV-VG. Compared to VCV, PCV-VG did not significantly affect the values of potential of hydrogen (pH) and partial pressure of end-tidal carbon dioxide (PetCO<sub>2</sub>). The subgroup analysis only showed that PCV had higher Cdyn than VCV in prone position. PCV-VG was superior to VCV in Cdyn and Ppeak, PCV only achieved higher Cdyn than VCV for prone position. The three modes did not differ in Vt, Pmean, PetCO<sub>2,</sub> pH, PaCO<sub>2</sub>, PaO<sub>2</sub>, OI, and PPCs for patients undergoing non-cardiothoracic surgery. We evaluate the effect of pressure controlled volume guaranteed ventilation (PCV-VG) on on intraoperative respiratory mechanics, oxygenation and postoperative pulmonary complications.PCV-VG results in significantly higher Cdyn and lower Ppeak compared to VCV.PCV-VG, PCV, and VCV did not have significant impacts on Vt, PaCO<sub>2</sub>, PaO<sub>2</sub>, OI, Pmean, and PPCs. We evaluate the effect of pressure controlled volume guaranteed ventilation (PCV-VG) on on intraoperative respiratory mechanics, oxygenation and postoperative pulmonary complications. PCV-VG results in significantly higher Cdyn and lower Ppeak compared to VCV. PCV-VG, PCV, and VCV did not have significant impacts on Vt, PaCO<sub>2</sub>, PaO<sub>2</sub>, OI, Pmean, and PPCs.
DOI: 10.6084/m9.figshare.29378173
title: Assessing individual genetic susceptibility to metabolic syndrome: interpretable machine learning method

description: Genome-wide association studies have provided profound insights into the genetic aetiology of metabolic syndrome (MetS). However, there is a lack of machine-learning (ML)-based predictive models to assess individual genetic susceptibility to MetS. This study utilized single-nucleotide polymorphisms (SNPs) as variables and employed ML-based genetic risk score (GRS) models to predict the occurrence of MetS, bringing it closer to clinical application. Feature selection was performed using Least Absolute Shrinkage and Selection Operator. Six ML algorithms were employed to construct GRS models. A fivefold cross-validation was utilized to aid in the internal validation of models. The receiver operating characteristic (ROC) curve was used to select the better-performing GRS model. The SHapley Additive exPlanations (SHAP) was then applied to interpret the model. After extracting GRS, stratified analysis of BMI, age and gender was performed. Finally, these conventional risk factors and GRS were integrated through multivariate logistic regression to establish a combined model. A total of 17 SNPs were selected for analysis. Among the GRS models, the extreme gradient boosting (XGBoost) model demonstrated superior discriminative performance (AUC = 0.837). The XGBoost’s optimal robustness was also validated through five-fold cross-validation (mean ROC-AUC = 0.706). The XGBoost-based SHAP algorithm not only elucidated the global effects of 17 SNPs across all samples, but also described the interaction between SNPs, providing a visual representation of how SNPs impact the prediction of MetS in an individual. There was a strong correlation between GRS and MetS risk, particularly observed among young individuals, males and overweight individuals. Furthermore, the model combining conventional risk factors and GRS exhibited excellent discriminative performance (AUC = 0.962) and outstanding robustness (mean ROC-AUC = 0.959). This study established a reliable XGBoost-based GRS model and a GRS prediction platform (https://metabolicsyndromeapps.shinyapps.io/geneticriskscore/) to assess individual genetic susceptibility to MetS. This model has high interpretability and can provide personalized reference for determining the necessity of primary prevention measures for MetS. Additionally, there may be interactions between traditional risk factors and GRS, and the integration of both in a comprehensive model is useful in the prediction of MetS occurrence.
DOI: 10.6084/m9.figshare.29378173.v1
title: Assessing individual genetic susceptibility to metabolic syndrome: interpretable machine learning method

description: Genome-wide association studies have provided profound insights into the genetic aetiology of metabolic syndrome (MetS). However, there is a lack of machine-learning (ML)-based predictive models to assess individual genetic susceptibility to MetS. This study utilized single-nucleotide polymorphisms (SNPs) as variables and employed ML-based genetic risk score (GRS) models to predict the occurrence of MetS, bringing it closer to clinical application. Feature selection was performed using Least Absolute Shrinkage and Selection Operator. Six ML algorithms were employed to construct GRS models. A fivefold cross-validation was utilized to aid in the internal validation of models. The receiver operating characteristic (ROC) curve was used to select the better-performing GRS model. The SHapley Additive exPlanations (SHAP) was then applied to interpret the model. After extracting GRS, stratified analysis of BMI, age and gender was performed. Finally, these conventional risk factors and GRS were integrated through multivariate logistic regression to establish a combined model. A total of 17 SNPs were selected for analysis. Among the GRS models, the extreme gradient boosting (XGBoost) model demonstrated superior discriminative performance (AUC = 0.837). The XGBoost’s optimal robustness was also validated through five-fold cross-validation (mean ROC-AUC = 0.706). The XGBoost-based SHAP algorithm not only elucidated the global effects of 17 SNPs across all samples, but also described the interaction between SNPs, providing a visual representation of how SNPs impact the prediction of MetS in an individual. There was a strong correlation between GRS and MetS risk, particularly observed among young individuals, males and overweight individuals. Furthermore, the model combining conventional risk factors and GRS exhibited excellent discriminative performance (AUC = 0.962) and outstanding robustness (mean ROC-AUC = 0.959). This study established a reliable XGBoost-based GRS model and a GRS prediction platform (https://metabolicsyndromeapps.shinyapps.io/geneticriskscore/) to assess individual genetic susceptibility to MetS. This model has high interpretability and can provide personalized reference for determining the necessity of primary prevention measures for MetS. Additionally, there may be interactions between traditional risk factors and GRS, and the integration of both in a comprehensive model is useful in the prediction of MetS occurrence.
DOI: 10.6084/m9.figshare.28121546
title: Effects of multidomain lifestyle intervention on frailty among older men and women – a secondary analysis of a randomized clinical trial

description: Frailty is a common geriatric syndrome associated with poor clinical outcomes. Effectiveness of lifestyle intervention programmes among frail older people has been examined earlier, but effects of interventions on prevention of frailty have been rarely studied. The aim of this study was to investigate to what extent the multidomain lifestyle intervention in the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) affected changes in frailty status among older men and women at risk of cognitive disorders. The 2-year multidomain lifestyle intervention trial including simultaneous nutritional counseling, physical exercise, cognitive training and social activity, and management of metabolic and vascular risk factors, was conducted among 1259 older people (mean age 68.9 years). A modified Fried’s frailty phenotype (weight loss, exhaustion, weakness, slowness, and low physical activity) was used to assess frailty at baseline and after the 2-year intervention. Participants with one or more components of the frailty phenotype were classified as pre-frail or frail. A multinomial regression model was applied to investigate efficacy of the intervention on frailty. We observed a favorable trend in reversing frailty among older men with the intervention. Pre-frail or frail men in the intervention group had higher probability of being non-frail after the intervention (44%) than pre-frail or frail men in the control group (30%) (<i>p</i> = 0.040). Among men, the intervention was especially beneficial in terms of increasing physical activity. Among women, multidomain lifestyle intervention did not affect the frailty status. Modifying lifestyle-related factors may have potential to reverse first signs of frailty among older men. However, the intervention lasted only two years, therefore, research with longer follow-up is needed to see possible long-term effects of lifestyle management on the development of frailty.
DOI: 10.6084/m9.figshare.28121546.v1
title: Effects of multidomain lifestyle intervention on frailty among older men and women – a secondary analysis of a randomized clinical trial

description: Frailty is a common geriatric syndrome associated with poor clinical outcomes. Effectiveness of lifestyle intervention programmes among frail older people has been examined earlier, but effects of interventions on prevention of frailty have been rarely studied. The aim of this study was to investigate to what extent the multidomain lifestyle intervention in the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) affected changes in frailty status among older men and women at risk of cognitive disorders. The 2-year multidomain lifestyle intervention trial including simultaneous nutritional counseling, physical exercise, cognitive training and social activity, and management of metabolic and vascular risk factors, was conducted among 1259 older people (mean age 68.9 years). A modified Fried’s frailty phenotype (weight loss, exhaustion, weakness, slowness, and low physical activity) was used to assess frailty at baseline and after the 2-year intervention. Participants with one or more components of the frailty phenotype were classified as pre-frail or frail. A multinomial regression model was applied to investigate efficacy of the intervention on frailty. We observed a favorable trend in reversing frailty among older men with the intervention. Pre-frail or frail men in the intervention group had higher probability of being non-frail after the intervention (44%) than pre-frail or frail men in the control group (30%) (<i>p</i> = 0.040). Among men, the intervention was especially beneficial in terms of increasing physical activity. Among women, multidomain lifestyle intervention did not affect the frailty status. Modifying lifestyle-related factors may have potential to reverse first signs of frailty among older men. However, the intervention lasted only two years, therefore, research with longer follow-up is needed to see possible long-term effects of lifestyle management on the development of frailty.
DOI: 10.6084/m9.figshare.29850193
title: Extracorporeal shock wave therapy for peripheral arterial disease-related intermittent claudication: a systematic review and meta-analysis

description: Intermittent claudication (IC) is a common manifestation of peripheral arterial disease. This study evaluates the efficacy of extracorporeal shock wave therapy (ESWT), a non-invasive treatment, for patients with IC. A systematic review and meta-analysis of four major databases (PubMed, Embase, Cochrane Library, Web of Science) was conducted through March 2025. Eight studies met inclusion criteria for the analysis, which was performed using Review Manager 5.4 with evidence strength assessed by the GRADE system. The analysis included eight studies with a total of 332 patients (mean age &gt;50 years, 67.5% male). Compared to placebo, ESWT demonstrated significant improvements in functional outcomes. It led to substantial increases in both Pain-Free Walking Distance (MD=26.53, <i>p</i> &lt; 0.01) and Maximum Walking Distance (MD=37.21, <i>p</i> &lt; 0.01). Quality of life was also enhanced, reflected by higher scores on the EQ-5D-3L survey (MD=0.08, <i>p</i> &lt; 0.01) and improvements across SF-36 domains including Physical Function, General Health, Vitality, and Social Functioning. However, ESWT did not produce a significant change in the Ankle-Brachial Index (ABI) (MD=−0.01, <i>p</i> = 0.05). ESWT is associated with improved walking distance and quality of life in patients with IC. These findings require cautious interpretation due to the limited number of studies and small sample sizes. Not applicable. This meta-analysis evaluates the effects of extracorporeal shock wave therapy (ESWT) on walking distance and functional scores in patients with intermittent claudication (IC).ESWT is an effective treatment for patients with IC, leading to improvements in pain-free walking distance, maximum walking distance, and quality of life.Future research on ESWT for intermittent claudication (IC) should focus on larger, multi-center trials with diverse patient populations to improve generalizability and statistical power. This meta-analysis evaluates the effects of extracorporeal shock wave therapy (ESWT) on walking distance and functional scores in patients with intermittent claudication (IC). ESWT is an effective treatment for patients with IC, leading to improvements in pain-free walking distance, maximum walking distance, and quality of life. Future research on ESWT for intermittent claudication (IC) should focus on larger, multi-center trials with diverse patient populations to improve generalizability and statistical power.
DOI: 10.6084/m9.figshare.29850193.v1
title: Extracorporeal shock wave therapy for peripheral arterial disease-related intermittent claudication: a systematic review and meta-analysis

description: Intermittent claudication (IC) is a common manifestation of peripheral arterial disease. This study evaluates the efficacy of extracorporeal shock wave therapy (ESWT), a non-invasive treatment, for patients with IC. A systematic review and meta-analysis of four major databases (PubMed, Embase, Cochrane Library, Web of Science) was conducted through March 2025. Eight studies met inclusion criteria for the analysis, which was performed using Review Manager 5.4 with evidence strength assessed by the GRADE system. The analysis included eight studies with a total of 332 patients (mean age &gt;50 years, 67.5% male). Compared to placebo, ESWT demonstrated significant improvements in functional outcomes. It led to substantial increases in both Pain-Free Walking Distance (MD=26.53, <i>p</i> &lt; 0.01) and Maximum Walking Distance (MD=37.21, <i>p</i> &lt; 0.01). Quality of life was also enhanced, reflected by higher scores on the EQ-5D-3L survey (MD=0.08, <i>p</i> &lt; 0.01) and improvements across SF-36 domains including Physical Function, General Health, Vitality, and Social Functioning. However, ESWT did not produce a significant change in the Ankle-Brachial Index (ABI) (MD=−0.01, <i>p</i> = 0.05). ESWT is associated with improved walking distance and quality of life in patients with IC. These findings require cautious interpretation due to the limited number of studies and small sample sizes. Not applicable. This meta-analysis evaluates the effects of extracorporeal shock wave therapy (ESWT) on walking distance and functional scores in patients with intermittent claudication (IC).ESWT is an effective treatment for patients with IC, leading to improvements in pain-free walking distance, maximum walking distance, and quality of life.Future research on ESWT for intermittent claudication (IC) should focus on larger, multi-center trials with diverse patient populations to improve generalizability and statistical power. This meta-analysis evaluates the effects of extracorporeal shock wave therapy (ESWT) on walking distance and functional scores in patients with intermittent claudication (IC). ESWT is an effective treatment for patients with IC, leading to improvements in pain-free walking distance, maximum walking distance, and quality of life. Future research on ESWT for intermittent claudication (IC) should focus on larger, multi-center trials with diverse patient populations to improve generalizability and statistical power.
DOI: 10.6084/m9.figshare.29422980
title: Clinical characteristic of isolated thrombocytopenia in patients with bone marrow failure-related germline variants: a retrospective study from a single centre

description: Immune thrombocytopenia (ITP) comprises the majority of thrombocytopenia. Some patients respond poorly to first-line ITP therapy or develop pancytopenia years later. Recent studies link heterozygous germline variants in acquired aplastic anemia (AA), yet their role in isolated thrombocytopenia carrying bone marrow failure-related germline variants (ITGV-BMFs) remains unclear. While whole-exome sequencing (WES) detects these variants, its cost limits routine use. This study compares prognosis and clinical features of isolated thrombocytopenia in patients with ITGV-BMFsand those with classic ITP. The clinical data of patients diagnosed with ITGV-BMFs were retrospectively analyzed and compared with those of patients with classic ITP from August 2018 to February 2024. The baseline characteristics, genomic systematically background, previous treatment response as well as their follow-up outcomes were compared. Patients with ITGV-BMFs demonstrated earlier onset age (<i>p</i> &lt; 0.001), lower bleeding scores and CD34%, along with elevated mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), and reticulocyte (RET) counts (<i>p</i> &lt; 0.001). Multivariate logistic regression analysis showed that the patients with ITGV-BMFs may possess distinct characteristics, including an earlier age at onset (<i>p</i> = 0.014) and lower bleeding score (<i>p</i> = 0.048). Notably, MCV and RET showed promising performance in receiver operating characteristic (ROC) curve analysis. During the follow-up period, 57.69% (15/26) ITGV-BMFs patients were further confirmed as aplastic anemia (AA, <i>n</i> = 13) or myelodysplastic syndrome (MDS, <i>n</i> = 2), with a median progression-free survival (PFS) of 7.25 years (<i>p</i> &lt; 0.0001). ITGV-BMFs may be diagnosed early using elevated MCV and reticulocyte counts, a diagnostic approach that may lead to earlier intervention and improved prognosis. Isolated thrombocytopenia carrying bone marrow failure-related germline variants (ITGV-BMFs) showed poorer response and prognosis.The median progress time of ITGV-BMFs was 7.25 years, with an incidence of 57.69% (15/26).ITGV-BMFs can be identified with elevated mean corpuscular volume (MCV) and reticulocyte (RET) in early stage. Isolated thrombocytopenia carrying bone marrow failure-related germline variants (ITGV-BMFs) showed poorer response and prognosis. The median progress time of ITGV-BMFs was 7.25 years, with an incidence of 57.69% (15/26). ITGV-BMFs can be identified with elevated mean corpuscular volume (MCV) and reticulocyte (RET) in early stage.
DOI: 10.6084/m9.figshare.29422980.v1
title: Clinical characteristic of isolated thrombocytopenia in patients with bone marrow failure-related germline variants: a retrospective study from a single centre

description: Immune thrombocytopenia (ITP) comprises the majority of thrombocytopenia. Some patients respond poorly to first-line ITP therapy or develop pancytopenia years later. Recent studies link heterozygous germline variants in acquired aplastic anemia (AA), yet their role in isolated thrombocytopenia carrying bone marrow failure-related germline variants (ITGV-BMFs) remains unclear. While whole-exome sequencing (WES) detects these variants, its cost limits routine use. This study compares prognosis and clinical features of isolated thrombocytopenia in patients with ITGV-BMFsand those with classic ITP. The clinical data of patients diagnosed with ITGV-BMFs were retrospectively analyzed and compared with those of patients with classic ITP from August 2018 to February 2024. The baseline characteristics, genomic systematically background, previous treatment response as well as their follow-up outcomes were compared. Patients with ITGV-BMFs demonstrated earlier onset age (<i>p</i> &lt; 0.001), lower bleeding scores and CD34%, along with elevated mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), and reticulocyte (RET) counts (<i>p</i> &lt; 0.001). Multivariate logistic regression analysis showed that the patients with ITGV-BMFs may possess distinct characteristics, including an earlier age at onset (<i>p</i> = 0.014) and lower bleeding score (<i>p</i> = 0.048). Notably, MCV and RET showed promising performance in receiver operating characteristic (ROC) curve analysis. During the follow-up period, 57.69% (15/26) ITGV-BMFs patients were further confirmed as aplastic anemia (AA, <i>n</i> = 13) or myelodysplastic syndrome (MDS, <i>n</i> = 2), with a median progression-free survival (PFS) of 7.25 years (<i>p</i> &lt; 0.0001). ITGV-BMFs may be diagnosed early using elevated MCV and reticulocyte counts, a diagnostic approach that may lead to earlier intervention and improved prognosis. Isolated thrombocytopenia carrying bone marrow failure-related germline variants (ITGV-BMFs) showed poorer response and prognosis.The median progress time of ITGV-BMFs was 7.25 years, with an incidence of 57.69% (15/26).ITGV-BMFs can be identified with elevated mean corpuscular volume (MCV) and reticulocyte (RET) in early stage. Isolated thrombocytopenia carrying bone marrow failure-related germline variants (ITGV-BMFs) showed poorer response and prognosis. The median progress time of ITGV-BMFs was 7.25 years, with an incidence of 57.69% (15/26). ITGV-BMFs can be identified with elevated mean corpuscular volume (MCV) and reticulocyte (RET) in early stage.